Figure 6.

In vivo treatment of C57BL/6 mice bearing Vk*MYC MM reveals lack of therapeutic activity when panobinostat is combined with ABT-737 above that of panobinostat treatment alone. (a) Single-agent therapy consisting of vehicle (D5W), high-dose panobinostat (25 mg/kg days 1–4, 15 mg/kg remainder, 5 days per week), ABT-737 (75 mg/kg, 5 days per week) or the combination of both agents in mice bearing Vk*MYC MM. Normalized M-spike data over the 18 days of treatment. (b) Survival of mice treated with vehicle (D5W, n=6), panobinostat (n=5), ABT-737 (n=5) or the combination of both agents (n=6). (c) Mice bearing Vk*MYC MM were then treated with lower doses of both agents as follows: vehicle (n=5); panobinostat (5 mg/kg, 5 days per week, n=5); ABT-737 (50 mg/kg, two times daily, n=5); or the combination of both agents (n=6), for 4 weeks. Results are depicted as normalized M-spike over the 26 days of treatment, and (d) survival of mice treated with the lower doses of both agents, alone and in combination. *P<0.05 versus vehicle